Hepatitis C Clinical Trial
Official title:
Use of Mucomyst (NAC) to Ameliorate Oxidant Stress as Measured by Surrogate Serum in Patients With Hepatitis C
The study will examine the effects of treatment with N-acetylcysteine ( Mucomyst ) 1 gm twice a day for 30 dyas in 15 patients with hepatitis C. The primary outcome of interest wil be the changes in oxidant stress as measured by different oxidant stress markers level in sera. Secondary outcomes of interest will be changes in viral load of hep C and changes in liver function
The Effects of N-Acetylcysteine on Oxidative Stress in Chronic Hepatitis C
Objective:
There is evidence that suggests oxidative stress plays a role in the pathologic mechanism of
disease progression in chronic hepatitis C virus infection (HCV). This study will test the
hypothesis that N-acetylcysteine given over one month will decrease oxidative stress and thus
slow disease progression.
Background:
Chronic hepatitis C is the most common blood borne infection in the United States. An average
of 230,000 new infections occurred each year during the 1980s, although since 1989 the annual
number of new infections has declined by greater than 80% to 36,000 by 1996.1,2,3 A CDC
survey in 2003 showed that annual new cases had declined to 30,000.4 The Third National
Health and Nutrition Examination Survey (NHANES III), conducted during 1988-1994, indicated
that an estimated 3.9 million (1.8%) Americans have been infected with HCV. In the general
population, the highest prevalence rates of HCV infection are found among persons aged 30-49
years and among males. Unlike the racial/ethnic pattern of acute disease, African Americans
have a substantially higher prevalence of HCV infection than do whites.5 Population-based
studies indicate that 40% of chronic liver disease is HCV-related, resulting in estimated
deaths of 8,000-10,000 each year. According to the CDC, estimated medical and work-loss costs
of HCV-related acute and chronic liver disease are greater than $600 million annually, and
HCV-associated end-stage liver disease is the most frequent indication for liver
transplantation among adults.1
After an acute infection, chronic HCV infection develops in most persons (75%-85%). 6 The
course of chronic HCV is insidious, progressing at a slow rate without symptoms or physical
signs in the majority of patients during the first two or more decades. Cirrhosis develops in
10%-20% of persons with chronic HCV over a period of 20-30 years, and hepatocellular cancer
in 1%-5%.7
HCV replicates in the hepatocytes, but it is not directly hepatotoxic. Lymphocytes recognize
infected cells and initiate an immune response. Damage to the liver parenchyma is mediated by
inflammatory cytokines, although the mechanism of disease progression is not clearly
understood. Jain et al. and Pratico et al. have shown that oxidative stress may be a factor
in progression to fibrosis and cirrhosis.8,9 It is believed that oxidative stress occurs via
various mechanisms including the reduction of NAD to NADH that causes a redox change and
inhibition of xanthine dehydrogenase activity resulting in a shift of purine oxidation to
xanthine oxidase, thereby promoting the generation of oxygen-free radical species. A
depletion in glutathione (GSH) has also been found in chronic liver disease which impairs
defense against oxidative stress.10 Several other studies have attempted to evaluate for
oxidative stress associated with HCV, but until recently accurate markers for evaluation of
oxidative stress had not been determined. Studies attempting to treat chronic HCV with
interferon and antioxidant combination have been inconclusive due inability to appropriately
measure oxidative stress.11, 12
Guha et al. discuss that for a long time, assessment of lipid peroxidation in vivo was
restricted to tissue measurements of alkanes, malondialdehyde, or hydroxynonenal levels, all
of which have serious limitation in accurately assessing oxidative stress. Roberts and
coworkers discovered a series of novel prostaglandins, now termed F2-isoprostanes, which are
now considered the gold standard for assessment of oxidative injury in vivo. These
prostaglandins are formed initially in situ by oxidation of arachidonic acid containing
phospholipids, and then released by the action of phospholipase. These can be measured in
plasma or urine samples by using gas chromatography mass spectrometry or ELISA.13-16
Recently, Dr. Vallyathan's group in West Virginia demonstrated that total antioxidant status,
glutathione peroxidase, and isoprostane levels were increased in shipyard welders consistent
with oxidative stress secondary to their occupational exposures.17
N-acetylcysteine (NAC) is a precursor of reduced GSH. It is an acetylated form of amino acid
L-cysteine, and is an excellent source of sulfhydryl groups. It is converted in the body into
metabolites capable of stimulating GSH synthesis, promoting detoxification, and acting
directly as free radical scavengers. It has been used clinically for more than 30 years
primarily as a monolithic. It is now commonly used for pre-treatment to prevent renal injury
secondary to intravenous dye in patients with renal insufficiency. It is also a mainstay of
treatment in cases of acetaminophen overdose since the 1980s. In this time period, NAC has
been shown to be safe without any significant toxicity or side-effects.18 Other studies have
shown that NAC can prevent apoptosis and promote cell survival. It reduces endothelial
dysfunction, inflammation, fibrosis, cartilage erosion, and transplant prolongation.19 It has
also been useful in improving ischemia-reperfusion related liver injury, cocaine and methanol
related liver injury.20-23
Considering the above information, it would be worthwhile to evaluate the baseline oxidative
stress in patients with hepatitis C and note changes, if any after NAC treatment for 6
months. There have been no prospective studies thus far that have evaluated baseline
oxidative stress in Hep C patients on and off interferon treatments with evaluation of
F2-isoprostanes and followed up on lab markers after treatment with NAC.
Research design:
Ten patients with HCV proven by PCR, not on treatment, will be recruited from the VA GI
clinic patient population. Background data will be gathered from the charts and by a
questionnaire. Blood for baseline liver function tests including serum ferritin, serum
isoprostane, serum aconitase, plasma glutathione (GSH), glutathione peroxidase (GPx) and
total antioxidant status (TAS), will be obtained in all patients. These tests will be
repeated in each patient after 15 days and 1 month of NAC at 1000 mg by mouth twice a day.
Tests will again be repeated 30 days after stopping the study medication. Hep c mRNA will be
measured at baseline and at 30 days. The research protocol will be explained to the patient
and informed consent will be obtained prior to enrollment. For the volunteers travel expenses
and time, $25 will be given at the beginning and end of the study for participation.
Inclusion criteria will be as follows: Volunteers will be divided into 2 groups: healthy
patients and HCV patients not on interferon. Exclusion criteria will be as follows:
significantly decompensated liver cirrhosis of Child's Class C, patients with evidence of
liver mass or hepatocellular cancer. Patients who are pregnant or on antioxidant such at
Vitamin E or Vitamin C will also be excluded. Also patients with known allergy to
N-acetylcysteine will be excluded
Sample Size calculation:
Since each patient will be his own control ( reducing the potential confounding of age,
smoking, medicine, life style etc )assuming variance of 5% in the assay system of the
biomarkers, 15 patients will give 90% power to see 10% or more difference in aggregate level
of the oxidant biomarkers.
Statistical Analyses:
Baseline demographic (age, sex) and clinical data (symptoms, Child's Classification) will be
collected for each patient. This data will be compared between the three groups using
Student's t-test for continuous variables and either Chi-square or Fisher's exact tests for
non-parametric variables. The measured laboratory values in the three groups, for the
baseline and post N-acetylcysteine, will be compared by using the paired t-test.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT02992184 -
PoC-HCV Genedrive Viral Detection Assay Validation Study
|
N/A | |
Completed |
NCT03186313 -
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 |